contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  availableLanguages
  pageUrl
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


inside-information-update-for-bioretecs-remeostm-trauma-screw-european-marketing-authorization

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

availableLanguages

pageUrl

imgUrl

description

Bioretec is a medical technology company. The company specializes in the development of medical devices. The product portfolio includes, for example, implants for pediatric and adult orthopedics and other material for bone and soft tissue injuries. In addition to the main business, service and associated ancillary services are also offered. Bioretec operates worldwide with the largest presence in the Nordic region.

Bioretec solmi uuden myyntisopimuksen Yhdysvalloissa | Kauppalehti Otsikon mukaan, kyllä Jenkkimarkkina aukeaa.

Inderes              Bioretec allekirjoitti uuden siviilisairaaloita koskevan myynti- ja...    Bioretec Oy Lehdistötiedote 22.11.2024 klo 9.30Bioretec Oy on uraauurtava yritys, joka on keskittynyt biohajoavien ortopedisten implanttien kehittämiseen ja etenee seuraavaan innovatiivisten...

Inderes              Bioretecin RemeOs™-traumaruuvin kaupallistaminen Yhdysvalloissa etenee uuden...    Bioretec Oy Lehdistötiedote 20.11.2024 klo 15.30Bioretec Oy, biohajoavien ortopedisten implanttien edelläkävijä, etenee innovatiivisten RemeOs™-traumatuotteiden kaupallistamisessa seuraavaan...

Tässä on Antin tekemä uusi yhtiöraportti Bioretecista.  Bioretecin Q3 jäi odotuksistamme, mutta liikevaihto kasvoi silti vertailukauteen nähden vahvasti. Taustalla oli kausiluonteisuutta, joka tuli nyt ensimmäistä kertaa esiin yhtiön raportoidessa Q3-lukuja. Kiinassa hintojen lasku on jatkunut toimintaympäristön muuttuessa, mikä on tuonut painetta myyntikatteeseen. Yhtiö on toisaalta myös onnistunut kasvamaan Aasiassa. Laskemme ennusteitamme maltillisesti odotuksiamme alhaisemman liikevaihdon ja Kiinan toimintaympäristön heikentymisen vuoksi. Ennusteiden myötä myös tavoitehintamme laskee 2,4 euroon (aik. 2,6). Jyrkän kurssilaskun myötä arvostus on kuitenkin muuttunut houkuttelevammaksi. Nostammekin suosituksemme lisää-tasolle (aik. vähennä) yhtiön siirtyessä kohti traumaruuvin laajempaa kaupallistamisvaihetta.                   Inderes              Bioretec Q3'24: Askelmerkit kohdallaan traumaruuvin myyntiä varten - Inderes    Bioretecin Q3 jäi odotuksistamme, mutta liikevaihto kasvoi silti vertailukauteen nähden vahvasti.

Antille kiitos hyvästä haastiksesta. Kovasti oli CEO härkämäisellä asenteella yhtiön tulevaisuuden ja jopa vuoden 2025 suhteen.

Bioretecin toimitusjohtaja Alan Donze oli Antin haastattelussa.

Meinasin aamulla jo vastata että ei tällä kertaa. Saatiin haastattelu kuitenkin viime hetkillä sumplittua. Julkaisukin tulee varmaan kohtapuolin.

Bioretec

Bioretec Ltd Inside information 27 June 2024 at 10:30 p.m. EETBioretec Ltd., a pioneer in bioresorbable orthopedic implants, announces thataccording to the information received from the Notified...

<div class="abstract">Bioretec Ltd &nbsp; &nbsp;&nbsp;Inside information&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 27 June 2024 at 10:30 p.m. EET</div>Bioretec Ltd., a pioneer in bioresorbable orthopedic implants, announces thataccording to the information received from the Notified Body (Dekra), its European CE mark market authorization application for the RemeOs™ trauma screw hasreturned fromthe expert panel evaluation. Although the previously estimated timeline projected that the CE mark would be obtained by the end of Q2 2024, we now anticipate that it will be issued later beyond this timeline.The duration of the expert panel evaluation was a maximum of 60 days, and with this step now completed, Bioretec continues to work diligently towards finalizing the authorization processwith the Notified Body.Further enquiriesAlan Donze, CEO, tel. +358 40 663 5011Johanna Salko, CFO, tel.+358 40 754 8172Certified advisorNordic Certified Adviser AB, +46 70 551 67 29Bioretec in briefBioretec is a globally operating Finnish medical device company that continues to pioneer the application of biodegradable orthopedic implants. The company has built unique competencies in the biological interface of active implants to enhance bone growth and accelerate fracture healing after orthopedic surgery. The products developed and manufactured by Bioretec are used worldwide in approximately 40 countries. Bioretec is developing the new RemeOs™ product line based on a magnesium alloy and hybrid composite, introducing a new generation of strong biodegradable materials for enhanced surgical outcomes. The RemeOs™ implants are absorbed and replaced by bone, which eliminates the need for removal surgery while facilitating fracture healing. The combination has the potential to make titanium implants redundant and help clinics reach their Value-Based Healthcare targets while focusing on value for patients through efficient healthcare. The first RemeOs™ product market authorization has been received in the U.S. in March 2023, and in Europe the CE-mark approval process is currently on-going. Bioretec is positioning itself to enter the addressable USD 7 billion global orthopedic trauma market and become a game changer in surgical bone fracture treatment.&nbsp;Better healing - Better life.www.bioretec.com

Stay up to date with our newsletter